CEO at Atacana Group. Supporting the majority of the Top 10 Pharma Companies. Former Global Head of Competitive at Roche/Genentech and at Novartis Pharmaceuticals. I have 20 years of experience in the pharmaceutical and biotech industry.
I have supported investment decisions across multiple disease areas in Oncology, Cardiovascular, Metabolism, Respiratory, Neuroscience, Infectious Diseases, Ophthalmology and Rare Diseases
My current focus is on helping blockbuster products develop winning strategies.
In addition, I coach B2B business owners/CEOs that want to grow their consulting business from 6 figures to 7 figures.
It depends on the country but in most developed countries you are committing an illegal act by using a fake name to gain competitive advantage.
In the U.S. this will likely fall under under theft by deception and/or fraud. In the U.K. this would fall under "blagging".
In addition of this being an illegal behavior, it is also unethical what you are doing.